Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Nobelpharma
Age
18–65
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Male or female, non-smoker (no use within 3 months prior to screening), ≥ 18 and ≤ 65 years of age, with BMI \> 18.5 and \< 30.0 kg/m2 and body weight ≥ 50.0 kg for males and ≥ 45.0 kg for females
Females of childbearing potential who are sexually active with a male partner must be willing to use one of acceptable contraceptive method throughout the study and for 12 weeks after the last study drug administration
You may not be if
Any sign of eczema/dermatitis, skin lesion, wound, or infection at the application site, or any other conditions that would prevent a safe application of the gel formulation.
Laser or surgery at the gel application site within 2 weeks before the gel application.
Positive alcohol breath test, urine drug screen or urine cotinine test at screeningation
History of allergic reactions or hypersensitivity to sirolimus, sirolimus derivatives, or excipient of NPC-12G Gel
Use of any drugs known to induce or inhibit CYP3A4 metabolism within 30 days prior to the first study drug administration
Positive pregnancy test at screening
Breast-feeding subject
History of active tuberculosis or exposure to endemic areas within 8 weeks prior to QuantiFERON®-TB testing performed at screening
Positive QuantiFERON®-TB test with positive chest X-ray, indicating possible tuberculosis infection
Immunization with a live attenuated vaccine within 1 month prior to dosing or planned vaccination during the study and up to 3 weeks after the last study drug administration